According to filings with the U.S. Securities and Exchange Commission, Zura Bio is raising $79,996,220.00 in new funding. Sources indicate that as part of senior management Executive, Verender Badial played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Zura Bio
Zura Bio is a clinical-stage biotechnology company advancing ZB-168 in alopecia areata and other inflammatory diseases. ZB-168 is an anti IL7Ra inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura Bio aims to develop a portfolio of therapeutic indications for ZB-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in alopecia areata. This will build on Phase 1b data in Type 1 Diabetes demonstrating a favourable safety profile and strong biological rationale. Zura Bio is headquartered in London, UK with team members in the UK and USA.

To learn more about Zura Bio, visit http://zurabio.com/

Contact:
Verender Badial, Executive
858-247-0520
https://www.linkedin.com/in/verender-badial-1221a32/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.